Shopping Cart
- Remove All
Your shopping cart is currently empty
PF-06873600, a selective and orally bioavailable cyclin-dependent kinase (CDK) inhibitor (CDK2, CDK4, and CDK6 with Ki values of 0.09 nM, 0.13 nM, and 0.16 nM, respectively), has potential antineoplastic activity.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $52 | In Stock | |
| 5 mg | $123 | In Stock | |
| 10 mg | $198 | In Stock | |
| 25 mg | $372 | In Stock | |
| 50 mg | $619 | In Stock | |
| 100 mg | $987 | In Stock | |
| 200 mg | $1,330 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $127 | In Stock |
| Description | PF-06873600, a selective and orally bioavailable cyclin-dependent kinase (CDK) inhibitor (CDK2, CDK4, and CDK6 with Ki values of 0.09 nM, 0.13 nM, and 0.16 nM, respectively), has potential antineoplastic activity. |
| Targets&IC50 | CDK2:0.09 nM (Ki), CDK6:0.16 nM (Ki), CDK4:0.13 nM (Ki) |
| In vitro | PF-06873600 selectively targets, binds to and inhibits the activity of CDKs.?Inhibition of these kinases leads to cell cycle arrest, induction of apoptosis and inhibition of tumor cell proliferation.?CDKs, ATP-dependent serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation, are frequently overexpressed in tumor cells. |
| Synonyms | PF3600 |
| Molecular Weight | 471.52 |
| Formula | C20H27F2N5O4S |
| Cas No. | 2185857-97-8 |
| Smiles | C[C@@]1(O)CCC[C@H]1n1c2nc(NC3CCN(CC3)S(C)(=O)=O)ncc2cc(C(F)F)c1=O |
| Relative Density. | 1.47 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 83.33 mg/mL (176.73 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (7 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.